Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 11/20 | 0.69 |
| ▸ | SCN2A | Q99250 | 11/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4628731 | 0.84 | SCN5A (0.84) | SCN5ASCN2AKDM4EHPGDL3MBTL1 | |
| SCHEMBL4627550 | 0.82 | SCN2A (0.84) | SCN5ASCN2AKDM4EL3MBTL1 | |
| SCHEMBL4629468 | 0.82 | SCN2A (0.72) | SCN5ASCN2AKDM4EHPGDL3MBTL1 | |
| SCHEMBL4629273 | 0.81 | SCN5A (1.00) | SCN5ASCN2A | |
| SCHEMBL4629442 | 0.78 | LMNA (0.54) | SCN5ASCN2AKDM4EHPGDDRD4 | |
| SCHEMBL4628993 | 0.77 | SCN2A (0.79) | SCN5ASCN2AHPGDL3MBTL1ALDH1A1 | |
| SCHEMBL4628364 | 0.77 | SCN2A (1.00) | SCN5ASCN2AALDH1A1 | |
| SCHEMBL4628434 | 0.76 | SCN5A (0.68) | SCN5ASCN2AKDM4EHPGDPOLB | |
| SCHEMBL7110564 | 0.75 | SCN5A (0.62) | SCN5ASCN2AKDM4EHPGDL3MBTL1 | |
| SCHEMBL4629230 | 0.74 | SCN5A (0.68) | SCN5ASCN2AMMP3HDAC8PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1918272-A1 | Pharmaceutically active compounds and methods of use | Wyeth a Corporation of the State of Delaware (US) | 2008-05-07 | — | — | EP | disclosed |
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7041702-B1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | GBA1, CTSA, GAA | SCN5A 1196/4885SCN2A 1613/4885KDM4E 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.